We are an early stage Anglo-American biotech company with a novel and proprietary platform targeting viral protein synthesis.
Our drugs are designed to be effective for treatment resistant infections and rapidly mutating pathogens.
Our drugs are designed to treat influenza, hepatitis B, smallpox, COVID-19, and a further pipeline of viral pathogens.
Our development and manufacturing processes are proven, faster and more cost-efficient than those for biologics and vaccines.
Our drugs will be easy to administer and will be suitable for use as post-exposure prophylaxis.
The Challenge: Drug Resistance and Loss of Efficiency
Viral infections are a devastating global problem, as the world has seen with COVID-19, and we face a continued threat from established viruses such as influenza and hepatitis as well as the potential for future pandemics and an unquantifiable risk of biological warfare
Antiviral drugs and vaccines can lose their efficacy very rapidly as viruses develop mutations to become resistant, and responding to new variant pandemics takes time.
Loss of immune memory and rapid viral mutations impair development of vaccines with good long term efficacy.
Loss of vaccine efficacy against new strains with new mutations happens in an unpredictable manner.
Chronic viral infections treated with DAAs may become resistant to treatment or require long term chronic therapy with no functional cure.
Modulating the immune system does not treat the infection, so may not lower mortality or long term complications.
Recycled or repurposed older drugs have poor efficacy, and more effective newer drugs tend to have worse adverse event profiles.
Vionelix Pharmaceuticals’ Proprietary Technology
Meet RAPTOR-AI™, our artificial intelligence-assisted, oligonucleotide based drug development platform to design resistance-proof direct acting antiviral drugs.
RAPTOR-AI™ was developed to address mutation driven drug resistance. Drugs designed using our RAPTOR-AI™ platform will retain efficacy even against new mutant strains as well as preventing emergence of new strains.
We have intellectual property protection, covering our scientific methods and our AI-assistance package.
Vionelix USP:
Resistance to resistance…
RAPTOR-AI™ has been developed as a platform to enable us to rapidly design highly effective direct acting antiviral treatments where only limited therapies are available.
RAPTOR-AI™ is based on the well-established antisense oligonucleotide technologies plus a novel and proprietary approach to target viral protein synthesis.
Our drugs are designed to counteract the loss of treatment efficacy due to viral mutations and be resistant to the virus becoming resistant to the drug.
Basic Mechanism of Action
The viral genome is the starting point for our drug development process. RAPTOR-AI™ allows us to analyze the genome, identify the best targets and design the most appropriate approach to create a mutation resistant drug
Short chain antisense oligonucleotide drugs bind the mRNA to stop the translation machinery and stop the production of viral proteins, and new virus particles, stopping the infection in its tracks
These drugs are usually highly vulnerable to viruses developing mutations. Drugs we develop using RAPTOR-AI™ are designed to remove this vulnerability to mutations.
RAPTOR-AI™: A Novel Approach
RAPTOR-AI™
is Vionelix’s proprietary, patented, AI-assisted, mutation resistant antiviral drug development platform, the first of its kind in the world. It allows us to develop new chemical entities with unprecedented speed and specificity.
RAPTOR-AI™
has helped us design antisense oligonucleotide based, direct acting antiviral drugs which are immune to viruses developing mutations and new strains, and which will retain their efficacy.
RAPTOR-AI™
can be applied not only multiple viral infections, but its future applications include non-viral infections and therapy areas outside infectious diseases including oncology and immune system disorders.
RAPTOR-AI™: A Novel Approach
A highly effective treatment approach to acute and chronic hepatitis B infection
There are currently no functional cures for chronic hepatitis B infection with current modalities aimed to reduce but not completely arrest viral replication. RAPTOR-AI™ allows us to devise novel treatment approaches and delivery systems that aim to totally eliminate viral replication and provide a functional cure.
Efficient hepatic drug delivery
Chronic hepatitis B infection leads to a residual viral reservoir in hepatocytes. Due to the high uptake of antisense oligonucleotide based drugs into hepatocytes, the initial focus of our drug development with the RAPTOR-AI™ platform has been chosen to be hepatitis B.
Unmet medical need
R&D efforts in infectious diseases, including hepatitis B, utilizing ASO technologies have not taken the ability of viruses to mutate fully into account.
Positive regulatory evolution
RNA based technologies are increasingly demonstrating their ability to address unmet medical need in a rapid and specific manner. Leading agencies including FDA have recently published guidance for the development of new RNA based treatments reducing the regulatory burden and increasing certainty.
